Celldex Therapeutics Inc. (NASDAQ: CLDX) presented data from Phase 2 clinical trials showing that its drug candidate barzolvolimab improved quality ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE